VEGFA and Neurodevelopmental delay: Furthermore, current RCTs involving daprodustat have shown that for both NDD and DD patients, no trend of increasing plasma VEGF is observed in daprodustat-treated subjects when compared to placebo or rhEPO subjects (Brigandi et al., 2016; Holdstock et al., 2016; Akizawa et al., 2017; Holdstock et al., 2019; Meadowcroft et al., 2019).